NGM Biopharmaceuticals(NGM)
Search documents
NGM Biopharmaceuticals(NGM) - 2021 Q3 - Quarterly Report
2021-11-04 20:22
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-1679911 ...
NGM Biopharmaceuticals(NGM) - 2021 Q2 - Quarterly Report
2021-08-05 20:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-1679911 (Sta ...
NGM Biopharmaceuticals(NGM) - 2021 Q1 - Quarterly Report
2021-05-06 20:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-1679911 (St ...
NGM Biopharmaceuticals(NGM) - 2020 Q4 - Annual Report
2021-03-15 20:49
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 26-1679911 (State or other jurisdiction of i ...
NGM Biopharmaceuticals(NGM) - 2020 Q3 - Quarterly Report
2020-11-12 21:36
FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-1679911 ...
NGM Biopharmaceuticals(NGM) - 2020 Q2 - Quarterly Report
2020-08-12 20:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-1679911 (Sta ...
NGM Biopharmaceuticals(NGM) - 2020 Q1 - Quarterly Report
2020-05-13 20:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-1679911 (St ...
NGM Biopharmaceuticals(NGM) - 2019 Q4 - Annual Report
2020-03-17 20:33
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 26-1679911 (I.R.S. Employer Identification N ...
NGM Biopharmaceuticals(NGM) - 2019 Q3 - Quarterly Report
2019-11-12 21:28
WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from _______ to _______ Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jur ...
NGM Biopharmaceuticals(NGM) - 2019 Q2 - Quarterly Report
2019-08-12 20:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdic ...